KFF found that the 10 top-selling Part D drugs represented $47.7 billion of the $215.7 billion total gross Medicare Part D drug spending in 2021. Eliquis, a blood thinner by Bristol Myers Squibb, accounted for the most spending out of these 10 drugs at $12.6 billion.
Macrophage activation syndrome (MAS) is a rare complication of autoimmune inflammatory rheumatic diseases (AIIRD) characterized by a progressive and life-thr…
/PRNewswire/ — Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free…
Watch our videos featuring global rheumatology experts to learn about recent advances towards slowing organ damage progression in lupus. Discover how you can implement disease…
IL-18 binding protein (IL-18BP) is a natural regulatory molecule of the proinflammatory cytokine IL-18. It can regulate activity of IL-18 by high affinity binding. The…
To the Editor: In the case series presented by Müller et al. (Feb. 22 issue),1 CD19-targeting chimeric antigen receptor (CAR) T-cell therapy in patients with…
Science Advances has reported that Duke University researchers have validated a biomarkers of osteoarthritis that may be identified 2 years before the appearance of radiographic…
In an open-label, randomized, non-inferiority trial, rheumatoid arthritis patients in remission were subject to tapering of disease-modifying antirheumatic drugs (DMARDs), and while maintenance of remission…
AbstractBackground/Aims. Age has a significant impact on SLE. However, data on very late onset SLE (vlSLE) patients are scarce. We have characterized a lar
An investigational Toll-like receptor (TLR) antagonist was effective in reducing biomarkers and clinical symptoms of systemic lupus erythematosus (SLE) in a pilot trial, evidence that…
Incomplete lupus? Undifferentiated connective tissue disease? Pre-clinical autoimmune disease? During the lupus pod at RheumNow Live 2024, Dr. David Karp discussed the spectrum of autoimmune…
